Prevention of tuberculosis among people with diabetes

An estimated one quarter of the world’s population have latent tuberculosis infection, of whom 5-10% will go on to develop TB disease at some stage. Screening and preventive treatment of latent tuberculosis infection is considered essential for global TB control. Children who have been in contact with a highly infectious tuberculosis case, and people with HIV have already been targeted for preventive treatment of LTBI. Another such high-risk group is people with diabetes in tuberculosis-endemic countries.

Prevention of tuberculosis among people with diabetes

An estimated one quarter of the world’s population have latent tuberculosis infection, of whom 5-10% will go on to develop TB disease at some stage. Screening and preventive treatment of latent tuberculosis infection is considered essential for global TB control. Children who have been in contact with a highly infectious tuberculosis case, and people with HIV have already been targeted for preventive treatment of LTBI. Another such high-risk group is people with diabetes in tuberculosis-endemic countries.

The first clinical trial globally

We will perform the first randomized controlled trial globally to evaluate the efficacy and impact of preventive treatment of latent tuberculosis infection in people living with diabetes. We will randomize 3000 people with diabetes and latent tuberculosis in Tanzania and Uganda to a 12-week course of rifapentine and isoniazid preventive therapy or placebo, with cumulative incidence of tuberculosis disease over at least 24-months follow-up as primary endpoint.

"Globally, there are now an estimated 425 million people living with diabetes, but this number will increase significantly over the coming decades, especially in Sub-Saharan African countries such as Uganda and Tanzania."

Latest News

Follow our website and twitter for the latest news.

PROTID during the WHO technical consultation on Innovative TPT trial design meeting

From 15 to 17 September 2021, the WHO Global Tuberculosis Program, in collaboration with University College London and others partners had a virtual technical consultation. The consultation  focused on the Innovative Clinical Trial Designs for the evaluation of new TB preventive treatments. PROTID was present during this technical consultation and was represented by Reinout van Crevel (Radboudumc, Netherlands) and Willyhelmina Olomi (NIMR-MMRC, Tanzania), with a presentation titled ‘Prevention of tuberculosis among people with diabetes: example from the PROTID trial’.

continue reading

PROTID’s Semi-Annual Summer meeting 2021

On August 26th and September 23rd, PROTID and all her partners held their Semi-Annual meeting remotely to discuss the current state of business and the upcoming trial. With the delays over the last year due to the COVID-19 pandemic, the work towards the project’s objectives has been challenging for all partners. We are optimistically looking forward to the start of our trial and to continue with our hard work. We hope to soon be able to shed more light on the screening and preventive treatment for global TB control among people with diabetes.

continue reading

Latest News

Follow our website and twitter for the latest news.

PROTID during the WHO technical consultation on Innovative TPT trial design meeting

From 15 to 17 September 2021, the WHO Global Tuberculosis Program, in collaboration with University College London and others partners had a virtual technical consultation. The consultation  focused on the Innovative Clinical Trial Designs for the evaluation of new TB preventive treatments. PROTID was present during this technical consultation and was represented by Reinout van Crevel (Radboudumc, Netherlands) and Willyhelmina Olomi (NIMR-MMRC, Tanzania), with a presentation titled ‘Prevention of tuberculosis among people with diabetes: example from the PROTID trial’.

continue reading

PROTID’s Semi-Annual Summer meeting 2021

On August 26th and September 23rd, PROTID and all her partners held their Semi-Annual meeting remotely to discuss the current state of business and the upcoming trial. With the delays over the last year due to the COVID-19 pandemic, the work towards the project’s objectives has been challenging for all partners. We are optimistically looking forward to the start of our trial and to continue with our hard work. We hope to soon be able to shed more light on the screening and preventive treatment for global TB control among people with diabetes.

continue reading

PROTID launched in Uganda

This year’s World Diabetes Day, celebrated on November 14th 2020, was used as an opportunity to launch the PROTID project in Uganda. The team in Uganda decided to launch the project through community engagement activities and a media campaign.

 

continue reading

First publication PROTID

In the IJTLD article “Having diabetes and being underweight in Asia: a potent risk factor for tuberculosis’’, Professor Anthony Harries made a plea for studies to assess the value of targeted preventative therapy among people with diabetes.

continue reading

Kick-off meeting

In January 2020, the PROTID consortium met for the first time as a group during a two-day kick-off meeting in Mbeya, Tanzania. The meeting was a beautiful mixture of getting to know each other, learning about TB and diabetes, working on the PROTID preparations and becoming closer as a group of colleagues from around the world.

continue reading

PROTID receives EDCTP grant

The PROTID consortium has been granted 4,8 Million Euro for its programme to prevent tuberculosis among people with diabetes. The grant is part of the second ‘European and Developing Countries Clinical Trial Partnership’ (EDCTP), which is supported by the European Union. The PROTID project will run from January 2020 until July 2024. The consortium will be led by an experienced group of scientists and clinicians in the Netherlands, Uganda, Tanzania, United Kingdom and New Zealand.

 

 

continue reading